This HTML5 document contains 111 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
n14http://dbpedia.org/resource/File:
foafhttp://xmlns.com/foaf/0.1/
n21https://global.dbpedia.org/id/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n6http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n11http://
n20https://web.archive.org/web/20111002090238/http:/www.velcadethree.co.uk/
n16http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://www.takeda.com/press/
owlhttp://www.w3.org/2002/07/owl#
n12https://www.washingtonpost.com/ac2/wp-dyn/
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Takeda_Oncology
rdf:type
n6:Agent n6:SocialPerson dbo:Organisation owl:Thing dbo:Company wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 schema:Organization dbo:Agent
rdfs:label
Takeda Oncology
rdfs:comment
Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical. Takeda Oncology's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation to develop a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease, although none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.
foaf:name
Takeda Oncology
foaf:homepage
n11:www.takedaoncology.com
dbp:name
Takeda Oncology
foaf:depiction
n16:Velcade_Shot.jpg
dbo:location
dbr:Cambridge,_MA
dcterms:subject
dbc:Pharmaceutical_companies_of_the_United_States dbc:Takeda_Pharmaceutical_Company dbc:Companies_based_in_Cambridge,_Massachusetts dbc:Biopharmaceutical_companies dbc:Health_care_companies_based_in_Massachusetts dbc:2008_mergers_and_acquisitions dbc:Biotechnology_companies_of_the_United_States dbc:American_subsidiaries_of_foreign_companies dbc:Pharmaceutical_companies_established_in_1993 dbc:Life_sciences_industry dbc:Biotechnology_companies_established_in_1993
dbo:wikiPageID
2797422
dbo:wikiPageRevisionID
1036170544
dbo:wikiPageWikiLink
dbr:Ixazomib dbc:Pharmaceutical_companies_of_the_United_States dbr:Oncology dbr:Platelet dbr:Brentuximab_vedotin dbr:SNDA dbr:People dbc:Biopharmaceutical_companies dbr:Schering-Plough dbr:Campath dbr:Bortezomib dbr:Chemistry dbr:Food_and_Drug_Administration_(United_States) dbc:Health_care_companies_based_in_Massachusetts dbr:Takeda_Pharmaceutical dbc:Companies_based_in_Cambridge,_Massachusetts n14:Velcade_Shot.jpg dbr:Research dbc:2008_mergers_and_acquisitions dbr:Janssen-Cilag dbr:Commercialization dbr:Eptifibatide dbr:Takeda_Pharmaceutical_Company dbr:Proteasome dbr:Velcade dbc:Pharmaceutical_companies_established_in_1993 dbc:American_subsidiaries_of_foreign_companies dbr:Multiple_myeloma dbr:Subsidiary dbr:Johnson_&_Johnson dbr:Cardiovascular_diseases dbr:Sales_pipeline dbr:Therapeutic dbc:Biotechnology_companies_of_the_United_States dbr:Genzyme dbr:Biotechnology dbr:Pharmaceutical_Company dbr:Massachusetts dbr:Cambridge,_MA dbr:Cambridge,_Massachusetts dbc:Life_sciences_industry dbr:Inflammation dbc:Biotechnology_companies_established_in_1993 dbc:Takeda_Pharmaceutical_Company
dbo:wikiPageExternalLink
n12:A26797-2000Dec19%3Flanguage=printer n11:www.millennium.com n19:article_29939.html n11:www.takedaoncology.com n20:
owl:sameAs
n21:4rxNV wikidata:Q6858915
dbp:wikiPageUsesTemplate
dbt:Cbignore dbt:More_citations_needed dbt:Infobox_company dbt:Dead_link dbt:Reflist
dbo:thumbnail
n16:Velcade_Shot.jpg?width=300
dbp:bot
medic
dbp:date
June 2021
dbp:defunct
N/A
dbp:foundation
1993
dbp:homepage
n11:www.takedaoncology.com
dbp:industry
dbr:Biotechnology dbr:Pharmaceutical_Company
dbp:keyPeople
Christophe Bianchi, President
dbp:location
Cambridge, MA, United States
dbp:numEmployees
1200
dbp:parent
dbr:Takeda_Pharmaceutical_Company
dbp:products
Velcade for injection
dbp:type
dbr:Subsidiary
dbo:abstract
Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical. Takeda Oncology's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation to develop a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease, although none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research. It is particularly known for bringing bortezomib (marketed as Velcade) through clinical trials to approval for treatment of patients with multiple myeloma by the U.S. FDA, but has a growing clinical development pipeline of other product candidates. On May 14, 2008, Japanese company Takeda Pharmaceutical announced the completion of its acquisition of Millennium for US$25.00 per share in cash—a deal worth $8.8 billion. Takeda completed the acquisition through a tender offer and subsequent merger as a wholly owned subsidiary Millennium: The Takeda Oncology Company - with the name being simplified to Takeda Oncology in 2013.
prov:wasDerivedFrom
wikipedia-en:Takeda_Oncology?oldid=1036170544&ns=0
dbo:wikiPageLength
10337
dbo:foundingYear
1993-01-01
dbo:numberOfEmployees
1200
dbo:industry
dbr:Biotechnology dbr:Pharmaceutical_Company
dbo:parentCompany
dbr:Takeda_Pharmaceutical_Company
dbo:product
dbr:Bortezomib
dbo:type
dbr:Subsidiary
foaf:isPrimaryTopicOf
wikipedia-en:Takeda_Oncology